Information om | Engelska ordet BEVACIZUMAB

Exempel på hur man kan använda BEVACIZUMAB i en mening

• Drugs such as aflibercept, bevacizumab, ranibizumab, and pegaptanib can inhibit VEGF and control or slow those diseases.
• In context of lung cancer drug development, the cells have served as testing grounds for novel drugs - such as paclitaxel, docetaxel, and bevacizumab - both in vitro and in vivo through cell culture and xenografting, respectively.
• Other therapeutic options in this setting are pazopanib (Votrient), sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus (Afinitor), bevacizumab (Avastin), and aldesleukin.
• In 2005 bevacizumab and ranibizumab intravitreal injections for the treatment of wet-AMD caused a rise in injections to 252,000.
• On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab.
• Their laboratory research provided key preclinical data about an antibody to VEGF, which was later humanized to become bevacizumab (Avastin, Genentech).
• BCRF has funded basic research on genetic susceptibility to breast cancer, breast cancer stem cells, trastuzumab (Herceptin), anti-angiogenesis treatment with bevacizumab (Avastin), MRI imaging, aromatase inhibitors, tamoxifen; and also clinical trials of new treatments with the Translational Breast Cancer Research Consortium.
• In April 2015, ramucirumab was approved by FDA for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and fluoropyrimidine.
• Motesanib was originally investigated for effectiveness against advanced nonsquamous non-small-cell lung cancer (NSCLC), with Phase II trials indicating an effectiveness comparable to bevacizumab when they were both used in combination with paclitaxel/carboplatin.
• The use of the intravitreal anti VEGF agents namely bevacizumab and ranibizumab have been described recently.
• Atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, was approved in the United States in December 2018, for the first-line treatment of people with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.
• They can involve monoclonal antibodies such as bevacizumab, antibody derivatives such as ranibizumab (Lucentis), or orally-available small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF receptors rather than the VEGFs).
• FDA has approved three drugs, bevacizumab, sunitinib and sorafenib, that were developed for antiangiogenic actions and are used in the treatment of patients with specific cancer types.
• Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.
• Other potential therapeutic candidates under pivotal clinical trials concluding in March–April are vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2, among others.
• Treatment methods such as 810 nm diode laser ablation, bevacizumab and/or triamcinolone acetonide provided control to some of the ocular symptoms in a 64-year-old female patient.
• "Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion" Authors: Diana Iturralde, Richard Spaide, Catherine Meyerle, L Yannuzzi, Y Fisher, J Sorenson, J Slakter, J Klancnik, Investigative Ophthalmology & Visual Science 47 (13), 4273-4273, 2006.

Förberedelsen av sidan tog: 304,18 ms.